Optimi Health Announces Non-Brokered Private Placement

Rhea-AI Summary

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer, has announced a non-brokered private placement of up to 16,666,666 units at CAD$0.30 per unit, aiming to raise up to CAD$5,000,000. Each unit consists of one common share and half a warrant, with each full warrant allowing the purchase of an additional share at CAD$0.40 for two years.

The company plans to use the proceeds for business development in Australia and globally, commissioning new equipment for GMP production and analytical laboratory, and general working capital. Insiders may participate for up to CAD$500,000. The offering includes an accelerated expiry provision and a potential 4% finder's fee for qualified non-related parties.

Positive

• Potential to raise up to CAD$5,000,000 in capital
• Expansion of business development opportunities in Australia and globally
• Investment in GMP production and analytical laboratory equipment

Negative

• Potential dilution of existing shareholders due to new share issuance
• Insider participation may raise concerns about conflicts of interest

Vancouver, British Columbia--(Newsfile Corp. - August 7, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it intends to complete a non-brokered private placement of up to 16,666,666 units (each a "Unit") at CAD$0.30 per Unit for gross proceeds of up to CAD$5,000,000 (the "Offering").

Each Unit comprised of one (1) common share in the capital of the Company (each a "Common Share") and one-half of one (1/2) transferable Common Share purchase warrant (each whole warrant a "Warrant"). Each Warrant entitles the holder to acquire one (1) Common Share at CAD$0.40 for two (2) years from the date of issuance, subject to an accelerated expiry provision, whereby in the event the closing price of the Company's Common Shares on the Canadian Securities Exchange (the "Exchange") exceeds CAD$0.50 for a period of 20 consecutive trading days, at the Company's election, the period within which the Warrants are exercisable, will be reduced and the holders of the Warrants will be entitled to exercise their Warrants for a period of 30 days commencing on the day the Company provides notice, any outstanding Warrants not exercised during the 30 day period will expire.

It is anticipated that insiders of the Company may participate in the Offering for up to CAD$500,000. The issuance of Units to insiders will be considered a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on exemptions from the formal valuation requirements of MI 61-101 pursuant to section 5.5(a) and the minority shareholder approval requirements of MI 61-101 pursuant to section 5.7(1)(a) in respect of such insider participation as the fair market value of the transaction, insofar as it involves interested parties, will not exceed 25% of the Company's market capitalization.

The Company intends to use the net proceeds from the Offering to further commercialize business development opportunities in Australia and around the world, commissioning recently purchased equipment for its GMP production and analytical laboratory, and general working capital. All securities issued under the Offering, including securities issuable on exercise thereof, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws.

In connection with the Offering the Company may pay, to qualified non-related parties, a finder's fee in cash equal to 4% of the gross proceeds raised.

For more information, please contact:

OPTIMI HEALTH CORP.
Jacob Safarik, CFO
Telephone: (778) 897-3279
jacob@optimihealth.ca

For media inquiries, please contact:
Andrea Mestrovic
Andrea@weareverypolite.com

For investor inquiries, please contact:
Michael Kydd
investors@optimihealth.ca

For more information, please visit Optimi Health.

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN)

Optimi is the only psychedelics pharmaceutical manufacturer in Canada with both a Controlled Drugs and Substances Dealer's Licence and a Drug Establishment Licence (DEL). Specializing in controlled substances such as botanical psilocybin and MDMA, Optimi is dedicated to supplying safe, top-tier GMP-grade products and API to researchers, drug developers, and authorized patients in markets across the world.

Optimi's leadership is reinforced by state-of-the-art, GMP-compliant cultivation, formulation, and analytical facilities, purpose-built to develop proprietary formulations that meet the highest standards of quality and responsible sourcing. Located in Princeton, British Columbia, the two facilities total 20,000 square feet where all products are grown and manufactured in-house under strict GACP and GMP conditions, ensuring unparalleled quality and reliability. The Company is committed to being the most trusted and compassionate supplier of safe psychedelic drug candidates worldwide.

FORWARD‐LOOKING STATEMENTS:

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements") that relate to Optimi's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. Forward-looking statements made in this news release include the proposed use of the proceeds of the Offering. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/219051

FAQ

What is the price per unit in Optimi Health's (OPTHF) private placement offering?

Optimi Health Corp. (OPTHF) is offering units at CAD$0.30 per unit in its non-brokered private placement.

How much capital is Optimi Health (OPTHF) aiming to raise through this private placement?

Optimi Health Corp. (OPTHF) is aiming to raise up to CAD$5,000,000 through this non-brokered private placement.

What are the terms of the warrants included in Optimi Health's (OPTHF) offering?

Each full warrant allows the purchase of one common share at CAD$0.40 for two years, subject to an accelerated expiry provision.

How does Optimi Health (OPTHF) plan to use the proceeds from this private placement?

Optimi Health plans to use the proceeds for business development in Australia and globally, commissioning new equipment for GMP production and analytical laboratory, and general working capital.